Selecting Treatment Approaches in Hemophilia

Slides:



Advertisements
Similar presentations
Real-World Prophylaxis Experience: Perspectives from Clinical Practice Alfonso Iorio MD, PhD McMaster University Canada BeneF IX ® (nonacog alfa) is not.
Advertisements

THE DISORDER: HEMOPHILIA How did it pass through to each generation. How can it be treated.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.
NOACs for Cancer-Associated Thrombosis:
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
Improving the Diagnosis and Treatment of Seizures in Long-term Care
Prophylaxis Considerations for Teenagers and Young Adults With Severe Hemophilia.
Thrombosis, Cancer, and NOACs
The ABCs of AF.
Hemophilia Updates: Incorporating New Concepts Into Practice
Extended Half-life Factor Products in the Management of Hemophilia
Individualizing Prophylaxis in Hemophilia
Hot Topics in Hemophilia Nursing
Statins and the Elderly Patient
Antithrombotics and PAD: A New Paradigm in Practice
Oral Anticoagulants in AFa,b A Brief History.
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Surveying the Safety of NOACs in the Real World
HCV Screening.
Tailoring Hemophilia Prophylaxis Therapy
Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.
Seizures in the Elderly: Treatment and Special Considerations
Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer
Individualizing Factor Replacement Therapy for Patients With Hemophilia.
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
A Better Solution For Cancer Patients With VTE?
Gene Therapy: Past, Present, and Future
VTE in Cancer.
Program Goals Disclaimer Overview Assessing Disease Activity.
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Program Goals. Technological Advances in Longer-Acting Factor Replacement Therapy for Hemophilia.
Program Goals Overview Is NEDA a Reasonable Target?
Multidisciplinary Approaches to Managing Hemophilia
What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?
The Road to Quality Improvement in HER2-Positive Breast Cancer
CMV in the HSCT Recipient
Factor Xa Inhibitors in PAD
When Is Intrathecal Drug Delivery Appropriate?
Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B.
A Time for Change for Managing Patients With VTE Who Have Cancer
IgG-Fc Fusion Proteins and Immunomodulation: What Does the Science Tell Us?
Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.
Managing Age-Related Clinical Issues in Hemophilia
Considerations in Managing Seizures in Women
Extended Half-life Factor Products in the Management of Hemophilia
Program Goals Disclaimers Defining Refractory Seizures.
Updates From the 2015 Meetings in Hemophilia
Current Challenges in Managing Hemophilia
Optimizing Joint Health in Hemophilia
A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.
Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.
Current Controversies and Advances in Hepatorenal Syndrome
Treating Atypical Hemolytic Uremic Syndrome A Case Discussion
Clinical Challenges and Updates in Managing Seizure Clusters
The ABCs of AF.
An Unmet Need.
5 Good Minutes on Atrial Fibrillation-related Stroke
Program Goals Overview Is NEDA a Reasonable Target?
When Is Intrathecal Drug Delivery Appropriate?
So Many Guidelines, So Little Time:
Incorporating New PAH Treatments Into Clinical Practice
Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products? 
Dr. Festus Njuguna Moi University/MTRH
Exploring the Use of Adeno-Associated Virus for Gene Therapy
NAFLD and NASH in Europe and Canada
Examining the Role of Pharmacokinetics in Hemophilia
Navigating the Journey
Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens by Johannes Oldenburg Blood Volume 125(13):
Treating Pulmonary Embolism Today
Presentation transcript:

Selecting Treatment Approaches in Hemophilia

Program Goals

Joint Disease in Hemophilia

Goal of Hemophilia Prophylaxis

Long-term Goals of Prophylaxis

WFH Guidelines for the Management of Hemophilia

Trough Levels and Bleeding Rates

Strategies for Prolonging the Half-life of Clotting Factor

Clinical Studies of Extended Half-life Factor Drugs

Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)